Working collaboratively with patients, families, patient advocates, and healthcare professionals.
People living with diseases of abnormal mineralization need new treatment options. Inozyme Pharma is on a mission to find breakthrough treatments.
We are committed to supporting the needs of patients, families, and healthcare professionals by providing disease education materials, resources for connecting with patient support groups, and updates on current development programs.
We provide a no-cost genetic testing program to improve detection and understanding of two rare calcification disorders, ENPP1 Deficiency and ABCC6 Deficiency. For more information about our genetic testing program and to see if you are eligible to participate, please click here.
Living with ENPP1 Deficiency
The Balancing Act® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. The show featured ENPP1 Deficiency as part of its recurring “Behind the Mystery of Rare and Genetic Diseases” series to raise awareness for this rare, debilitating, and life-threatening mineralization disease for which there are currently no approved treatment options.
Janine Hicks, a patient living with ENPP1 Deficiency, and her parents Donna and Peter Hicks, discuss their experience with the disease, including her journey to diagnosis, current management options, and hope for future research. Professor Zulf Mughal, a treating physician and researcher and Consultant in Pediatric Bone Disorders, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, provides an overview of ENPP1 Deficiency, such as signs and symptoms, obtaining a diagnosis, and progression of disease throughout a patient’s life.